Announcements Trials
Browse Landscape

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Thrombosis 1Polycythemia Vera 1Polycythemia 1Neoplasms 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Cisplatin 11Cetuximab 10Radiotherapy 7Fluorouracil 6Docetaxel 5pembrolizumab 4Carboplatin 4figitumumab 3Radiation 3Paclitaxel 3Erlotinib Hydrochloride 3Bleomycin 3130-nm albumin-bound paclitaxel 3talimogene laherparepvec 2avelumab 2Surgical Procedures, Operative 2Oxaliplatin 2Lapatinib 2Capecitabine 2zalutumumab 1yeast-CEA vaccine 1temsirolimus 1temoporfin 1smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1selinexor 1remetinostat 1ponatinib 1patritumab 1nilotinib 1necitumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Squamous Cell × Phlebotomy × Clear all
NCT00507702 2019-04-18

Identification of Key Blood Molecular Markers for Immunotherapy

Stanford University

Terminated
191 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡